Fundraising FoxEQT Life Sciences — 2026 Investments
4 investments dated 2026 · listed companies and verified rows first · show all
Aerska develops RNA interference (RNAi) medicines designed for targeted delivery across the blood-brain barrier to treat, delay, and prevent central nervous system and neurological diseases.
BiotechDeep TechHealthtechMedical Devices
Stuart Milstein(Chief Platform Officer, Co-founder)inJack O’Meara(Chief Executive Officer, Co-founder)inDave Hardwicke(Director, Head of Business Development, Co-founder)
Co-investorsage1BackedBlueYard CapitalEntrepreneur FirstGlobal Health Investment CorporationIaso Ventures+6 more
RQ Bio discovers and develops long-acting monoclonal antibodies (LAAbs) targeting seasonal influenza to provide protection against severe viral disease.
BiotechHealthtech
Co-investorsFrazier Life SciencesLifeArc VenturesOxford Science EnterprisesWellington ManagementForbionMonograph Capital Partners+1 more
Vaderis develops a first-of-its-kind oral therapy for hereditary hemorrhagic telangiectasia (HHT), a rare vascular disease with no existing approved treatments.
BiotechHealthtechMedical Devices
Co-investorsDroia VenturesMedicxiGoldman Sachs
Xeltis develops implantable vascular devices that transform into living tissue using Restorex supramolecular polymer technology.
BiotechDeep TechHealthtechMedical Devices
Eliane Schutte(Chief Executive Officer)in
Co-investorsKurma PartnersVI PartnersYsios CapitalAmadeus Capital PartnersInvest-NL
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.